Amgen Inc. (NASDAQ:AMGN) has announced the purchase of Celgene Corporation’s (NASDAQ:CELG) leading immunology drug Otezla for around $13.4 billion. Otezla purchase deal to be finalized at the end of the year The company has indicated that the deal will be closed at the end of the year. Following the announcement, Amgen’s stock gained 2.85% to […]
NASDAQ:AMGN
Amgen, Inc. (NASDAQ:AMGN) And Array Biopharma Inc (NASDAQ:ARRY) Partners For Inflammation Discoveries
Amgen, Inc. (NASDAQ:AMGN) and Array Biopharma Inc (NASDAQ:ARRAY) have announced today the partnership agreement as an effort to discover and develop new drugs for autoimmune diseases. The unrevealed target and lead inhibitors were found out through the Array’s proprietary podium that leverages its capability in chemistry and early development. Array Biopharma made a deal with […]
Advaxis, Inc. (NASDAQ:ADXS) Gets IND Acceptance From The Food And Drug Administration For ADXS-NEO
Advaxis, Inc. (NASDAQ:ADXS) has revealed that the Food and Drug Administration of the United States has given the go-ahead for an application filed to try out ADXS-NEO. Development of the treatment is being done in partnership with Amgen, Inc. (NASDAQ:AMGN). “The IND acceptance is a landmark step towards escaping the one-size-fits-all approach to cancer treatments […]
What Is Going On With Plandai Biotechnology Inc (OTCMKTS:PLPL) And Amgen, Inc. (NASDAQ:AMGN)?
Plandai Biotechnology Inc (OTCMKTS:PLPL) is one of the OTC traded stocks that have been under investors radar in this year. Recently, the company confirmed an amendment to its previously finalized contract with USN Worldwide. As per the new deal, Plandai will expand its Phytofare® complex sales to USN and related contract manufacturer entities to the […]
Amgen, Inc. (NASDAQ:AMGN) Migraine Treatment Drug Passes Phase 2 Trials
In a breakthrough in migraine treatment, the Phase 2 results of the clinical trials of AMG 334 drug by Amgen, Inc. (NASDAQ:AMGN) has been successful. Competing with the existing migraine drugs, the monthly rates of migraine attacks were comparably less when using this medication. According to the company, the AMG 334 drug lowered the chance […]
Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round
Amgen, Inc. (NASDAQ:AMGN) has partnered up with Fidelity Biosciences to venture into the gene editing research field. The scientific community has recently shed more light on gene editing, citing the need for more focus on the subject. More finances have been allocated to the research, thus evidence of the rapidly growing appeal of the subject. […]
Juno Therapeutics Inc (NASDAQ:JUNO) and AstraZeneca plc (ADR) (NYSE:AZN) Pair Up for new Cancer Therapy
Juno Therapeutics Inc (NASDAQ:JUNO) and AstraZeneca plc (ADR) (NYSE:AZN) are collaborating to test their respective cancer therapies in tandem. The collaboration will combine new-fangled therapies that will use the immune system to combat tumours. Under the deal, the duo will jointly fund a Phase I study that combines Juno’s CAR-T therapy and antibodies developed by […]
Amgen, Inc. (NASDAQ:AMGN) Says Lancet Publishes Two Stage Three Trials Indicating Cholesterol-Lowering Medication Evolocumab
Boston, MA 10/03/2014 (wallstreetpr) – Amgen, Inc. (NASDAQ:AMGN) disclosed that the Lancet published data from two Stage three trials, TESLA and RUTHERFORD-2. The data pointed out that the treatment with novel investigational low-density lipoprotein cholesterol or LDL-C, evolocumab, resulted in a statistically important reduction in LDL-C. The data compared with the placebo in patients affected […]
Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors
Boston, MA 09/24/2014 (wallstreetpr) – Celgene Corporation (NASDAQ:CELG) could upset companies like AbbVie Inc (NYSE:ABBV), Amgen, Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE), which are currently minting hefty money through their psoriasis injections currently selling in the market. Celgene Corporation (NASDAQ:CELG) reported on Tuesday that it has received the approval from the Food and Drug Administration for […]
Amgen, Inc. (NASDAQ:AMGN)’s Chronic Heart Failure Drug Receives Priority Designation From FDA
Boston, MA 08/28/2014 (wallstreetpr) – The U.S. biotechnology company Amgen, Inc. (NASDAQ:AMGN) declared in its press report that it had received a green signal from the U.S. Food and Drug Administration (FDA) for the priority review designation for ‘ivabradine.’ The effectiveness of the oral drug Ivabradine: Ivabradine is an oral drug used for the treatment […]
Pfizer Inc. (NYSE:PFE) To Go For Test Of Xalkori Lung Cancer Drug And Merck & Co., Inc. (NYSE:MRK)’s Pembrolizumab Immunotherapy Combination
Boston, MA 08/27/2014 (wallstreetpr) – Pfizer Inc. (NYSE:PFE) said yesterday that it shall be performing clinical tests of its lung cancer drug called Xalkori with Merck & Co., Inc. (NYSE:MRK)’s pembrolizumab, its experimental immunotherapy. The company said that clinical tests were carried out in order to find out whether combination led to better results for […]
Amgen, Inc. (NASDAQ:AMGN)’s Subsidiary Says Earlier Positive Results On Kyprolis Are Enough To Support Regulatory Submissions
Boston, MA 08/14/2014 (wallstreetpr) – A global biotechnology company, Amgen, Inc. (NASDAQ:AMGN)’s subsidiary Onyx Pharmaceuticals, Inc. disclosed that the favorable results of ASPIRE stage three clinical trial would be enough to support regulatory submissions throughout the world on Kyprolis in patients affected by relapsed and advanced refractory multiple myeloma. ASPIRE Kyprolis was given approval by […]
BIND Therapeutics Inc (NASDAQ:BIND), Roche In Nanomedicine Collaboration
Boston, MA 06/20/2014 (wallstreetpr) – BIND Therapeutics Inc (NASDAQ:BIND), a nanomedicine company based in Cambridge, has announced its latest collaborative arrangement with another large drug company. It announced a partnership with Roche, a Swiss drug giant, to develop novel treatments, but outside its usual oncology therapeutic area. Bind is best known for developing of programmable treatments […]
Amgen, Inc. (NASDAQ:AMGN)’S Clinical Trials On Talimogene Laherparepvec Show Significant Response Rate
Boston, MA 06/05/2014 (wallstreetpr) – Amgen, Inc. (NASDAQ:AMGN) presented findings from two clinical trials on Talimogene laherparepvec at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago. The two clinical trials with the drug, which is a novel investigational drug employed in oncolytic immunotherapy involved evaluating the […]
Amgen, Inc. (NASDAQ:AMGN) Zeroing In On Allergic Asthma Treatment With Big Promise
Boston, MA 05/22/2014 (wallstreetpr) – The largest biotechnology company by sales, Amgen, Inc. (NASDAQ:AMGN), is on the brink of bringing an allergic asthma treatment that could become a game-changer in the market and the company’s financial books. The company manufactures and markets a wide range of treatments and like cancer, asthma treatment is gaining prominence among […]
Recent Stories
Why are Investors Eyeing Progressive Care, Inc. (RXMD)?
Q BioMed Inc. (QBIO) A Bull’s Tale of the Day
Get Prepared for the Resurgence of the CBD Theme (CURLF, GWPH, HMPQ, CVSI)
Intel Corporation (NASDAQ:INTC) Introduces Ponte Vecchio And Enters GPU Space: Intel Launches oneAPI, A Programming Interface For Developers